Among TET genes, alterations in TET2 are frequently reported in myeloid disorders, occurring in 10% of de novo AML, 30% of myelodysplastic syndrome (MDS) and almost 50% of chronic myelomonocytic leukemia (CMML) cases (Delhommeau et al., 2009; Papaemmanuil et al., 2016). Here, TET2 is linked to chronic myelomonocytic leukemia.